Form 4: Upstream Bio GC Granted Equity Awards

Upstream Bio's General Counsel, Allison Ambrose, was granted 17,000 restricted stock units and options to purchase 51,000 shares of common stock.

Summary

• Allison Ambrose, General Counsel of Upstream Bio, Inc. (UPB), acquired 17,000 shares of common stock in the form of Restricted Stock Units (RSUs) on January 2, 2026.
• These RSUs were granted pursuant to the Issuer's 2024 Stock Option and Incentive Plan and will vest in sixteen equal quarterly installments following January 1, 2026, contingent on continued service.
• Ambrose also acquired options to buy 51,000 shares of common stock with an exercise price of $27.07 per share on January 2, 2026.
• The options will vest in forty-eight equal monthly installments following January 1, 2026, subject to continued service, and expire on January 1, 2036.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event. While not a direct positive for immediate share price, it reflects standard corporate practice for aligning management incentives with shareholder interests, which is generally viewed as a neutral to slightly positive governance aspect.

Positives

• The equity grants align the interests of the General Counsel with those of the shareholders, incentivizing long-term performance and retention.
• The grants are part of the company's 2024 Stock Option and Incentive Plan, indicating a structured approach to executive compensation.

Risks

• The value of the equity awards is subject to the future market price of Upstream Bio's common stock, which can fluctuate.
• Vesting of both RSUs and stock options is contingent on the reporting person's continued service, meaning the awards could be forfeited if employment ceases before vesting is complete.

Future Outlook

The future outlook for the reporting person's beneficial ownership includes the vesting of 17,000 RSUs in sixteen equal quarterly installments and 51,000 stock options in forty-eight equal monthly installments, both commencing after January 1, 2026, subject to continued service.

Industry Context

The granting of equity awards such as restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation. It serves to attract, retain, and motivate key personnel by linking their financial incentives to the company's long-term performance and shareholder value.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting schedules, is consistent with common practices observed in publicly traded biotech companies of similar size and stage.
• The use of a formal 'Stock Option and Incentive Plan' is a standard corporate governance mechanism for managing equity compensation, comparable to plans at companies like Moderna or BioNTech for their executives.

Management Changes

Corporate Governance

Related Party Transactions

• The equity grants to Allison Ambrose, an officer of Upstream Bio, Inc., represent a compensation transaction between the company and a key executive, which is a common form of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The grants align the General Counsel's financial interests with long-term shareholder value creation, potentially leading to more focused decision-making.
• Employees: The compensation structure for executives can influence overall employee morale and perception of fairness in compensation practices.

Next Steps

• Continued service by Allison Ambrose for the vesting of RSUs and stock options.
• Future Form 4 filings will report subsequent vesting events or any dispositions of these securities.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, Allison Ambrose. Such grants are standard practice for executive compensation and serve to align management's interests with shareholders. The information presented does not introduce new material factors that would significantly alter the investment thesis or warrant a change in an existing 'hold' recommendation for Upstream Bio. It is a non-event in terms of immediate market impact or fundamental company performance.

Keywords

Upstream Bio, UPB, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Option, Executive Compensation, Allison Ambrose